Table 2.
Baseline attitudes towards injectable PrEP characteristics liked and disliked, by region, sex at birth and cohort
| Total (n = 199) |
Total (n = 199) |
Total (n = 199) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Regional comparisons | Sex-at-birth comparisons | Cohort comparisons | ||||||||
| Overall (n = 199) |
U.S. (n = 106) |
Non-U.S. (n = 93) |
P-value | Male (n = 67) | Female (n = 132) | P-value | C1 (n = 110) |
C2 (n = 89) |
P-value | |
| Liked characteristics (%) | ||||||||||
| Nothing | 2.5 | 2.8 | 2.1 | 0.76 | 3.0 | 2.3 | 0.76 | 3.6 | 1.1 | 0.26 |
| HIV prevention | 42.2 | 39.6 | 45.2 | 0.43 | 41.8 | 42.4 | 0.93 | 40.0 | 44.9 | 0.48 |
| Easier to use | 58.8 | 73.6 | 41.9 | < 0.01 | 61.2 | 57.6 | 0.62 | 60.9 | 56.2 | 0.50 |
| Long duration | 47.7 | 54.7 | 39.8 | 0.04 | 37.3 | 53.0 | 0.04 | 50.9 | 43.8 | 0.32 |
| Discreet | 14.1 | 17.9 | 9.7 | 0.10 | 7.5 | 17.4 | 0.06 | 13.6 | 10.1 | 0.84 |
| Offered by provider | 12.6 | 19.8 | 4.3 | < 0.01 | 9.0 | 14.4 | 0.27 | 12.7 | 4.5 | 0.94 |
| No interruption of sex | 13.6 | 20.7 | 5.4 | < 0.01 | 11.9 | 14.4 | 0.63 | 15.4 | 5.6 | 0.39 |
| Disliked characteristics (%) | ||||||||||
| Nothing | 24.1 | 14.1 | 35.5 | < 0.01 | 20.9 | 25.8 | 0.45 | 24.5 | 23.6 | 0.88 |
| No HIV prevention | 12.1 | 14.1 | 9.7 | 0.33 | 13.4 | 11.4 | 0.67 | 16.4 | 6.7 | 0.04 |
| Painful | 36.2 | 40.6 | 31.2 | 0.17 | 34.3 | 37.1 | 0.70 | 33.6 | 39.3 | 0.41 |
| Side effects | 40.7 | 46.2 | 34.4 | 0.09 | 38.8 | 41.7 | 0.70 | 39.1 | 42.7 | 0.61 |
| No reversal | 12.1 | 17.0 | 6.4 | 0.02 | 9.0 | 13.6 | 0.34 | 15.4 | 7.9 | 0.10 |
| Offered by provider | 7.0 | 8.5 | 5.4 | 0.39 | 6.0 | 7.6 | 0.68 | 10.0 | 3.4 | 0.07 |
| Not discreet | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | – | 0.0 | 0.0 | – |
| Cost | 14.1 | 21.7 | 5.4 | < 0.01 | 11.9 | 15.1 | 0.54 | 19.1 | 7.9 | 0.02 |